KR950031111A - Antibody conjugates with improved properties - Google Patents

Antibody conjugates with improved properties Download PDF

Info

Publication number
KR950031111A
KR950031111A KR1019950005739A KR19950005739A KR950031111A KR 950031111 A KR950031111 A KR 950031111A KR 1019950005739 A KR1019950005739 A KR 1019950005739A KR 19950005739 A KR19950005739 A KR 19950005739A KR 950031111 A KR950031111 A KR 950031111A
Authority
KR
South Korea
Prior art keywords
conjugate
antibody
carrier protein
seq
administering
Prior art date
Application number
KR1019950005739A
Other languages
Korean (ko)
Inventor
머래이 브랜던
오레일리 테렌스
플루쉬케 게르트
Original Assignee
베르너 발데크
시바-가이기 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베르너 발데크, 시바-가이기 아게 filed Critical 베르너 발데크
Publication of KR950031111A publication Critical patent/KR950031111A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Abstract

본 발명은 담체 단백질이 단클론성 항체에 공유 결합된 가용성 포합체, 상기 포합체로 이루어지는 약제 및 그의 제조 방법에 관한 것이다. 본 발명의 포합체는 예를 들면 포유류, 특히 사람의 활성 면역 치료에 유용하다.The present invention relates to a soluble conjugate in which a carrier protein is covalently bonded to a monoclonal antibody, a medicament consisting of the conjugate, and a method for producing the same. The conjugates of the present invention are useful, for example, in active immune treatment of mammals, especially humans.

Description

특성이 개선된 항체 포합체Antibody conjugates with improved properties

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (16)

1개 이상의 담체 단백질 분자가 1개의 항체 분자의 일정 부위에 부위 선택적으로 공유 결합되어 있는, 생체 내에서 면역 반응을 유도하는 가용성의 비응집성 담체 단백질-항체 포합체.A soluble, non-aggregated carrier protein-antibody conjugate that induces an immune response in vivo wherein one or more carrier protein molecules are site-selective covalently linked to a site of one antibody molecule. 제1항에 있어서, 담체 단백질이 박테리아 독소로부터 유도된 것인 포합체.The conjugate of claim 1, wherein the carrier protein is derived from a bacterial toxin. 제2항에 있어서, 담체 단백질이 CRM 197 또는 테타누스 톡소이드로 이루어진 군으로부터 선택된 것인 포합체.The conjugate of claim 2, wherein the carrier protein is selected from the group consisting of CRM 197 or tetanus toxoid. 제1항 내지 3항 중 어느 한 항에 있어서, 담체 단백질 및 항체 성분 간의 결합이 티오에테르 결합을 포함하는 것인 포합체.The conjugate according to any one of claims 1 to 3, wherein the bond between the carrier protein and the antibody component comprises a thioether bond. 제1항 내지 4항 중 어느 한 항에 있어서, 항체가 항-이디오타입 항체, 특히 고분자량의 흑종에 연관된 항원(HMW-MAA)상의 단클론성 항체로 인지되는 결정자의 내부 이미지인 항-이디오타입 항체인 포합체.The anti-id according to any one of claims 1 to 4, wherein the antibody is an internal image of a determinant recognized as an anti-idiotype antibody, in particular a monoclonal antibody on an antigen associated with high molecular weight melanoma (HMW-MAA). Conjugates that are iotype antibodies. 제5항에 있어서, 항체가 서열 확인 번호3에 제시된 아미노산 서열을 갖는 경쇄의 변이 도메인, 또는 서열 확인 번호 1에 제시된 아미노산 서열을 갖는 폴리펩티드 또는 서열 확인 번호 2에 제시된 아미노산 서열을 갖는 폴리펩티드로 이루어지는 군으로부터 선택된 중쇄의 변이 도메인으로 이루어지는 것인 포합체.The group of claim 5 wherein the antibody consists of a variant domain of a light chain having an amino acid sequence as set out in SEQ ID NO: 3, or a polypeptide having an amino acid sequence as set out in SEQ ID NO: 1 or a polypeptide having an amino acid sequence as set out in SEQ ID NO: 2. 7. Conjugate comprising a mutated domain of a heavy chain selected from. 제1항 내지 6항중 어느 한 항에 있어서, 인체 또는 동물체에 수행되는 진단 또는 치료법에 사용하기 위한 포합체.The conjugate according to any one of claims 1 to 6, for use in a diagnosis or treatment carried out on a human or animal body. 제7항에 있어서, 활성 면역 요법에 백신으로서 사용하기 위한 포합체.8. The conjugate of claim 7, for use as a vaccine in active immunotherapy. 제1항 내지 6항 중 어느 한 항에 있어서, 제약 조성물을 제조에 사용하기 위한 포합체.The conjugate according to any one of claims 1 to 6 for use in the manufacture of the pharmaceutical composition. 제1항 내지 6항 중 어느 한 항의 포합체, 제약적으로 허용가능한 담체 및 임의로 보조제로 이루어지는 제약 조성물.A pharmaceutical composition comprising the conjugate of any one of claims 1 to 6, a pharmaceutically acceptable carrier and optionally an adjuvant. 1개 이상의 담체 단백질 분자가 1개의 항체에 공유 결합되도록 하는 조건하에서 항체를 담체 단백질과 반응시키고, 목적 포합체를 단리하는 것으로 이루어지는, 제1항 내지 6항중 어느 한 항에 따른 포합체의 제조 방법.A method for producing a conjugate according to any one of claims 1 to 6, which comprises reacting an antibody with a carrier protein and isolating a target conjugate under conditions such that at least one carrier protein molecule is covalently bound to one antibody. . 1개 이상의 담체 단백질 분자가 1개의 항체 분자의 일정부위에 부위 선택적으로 공유 결합된 가용성의 비응집성 담체 단백질-항체 포합체를 투여하는 것으로 이루어지는 포유류, 특히 사람의 면역 반응 유발 방법.A method of inducing an immune response in a mammal, in particular a human, comprising administering a soluble, non-aggregated carrier protein-antibody conjugate wherein one or more carrier protein molecules are site-selective covalently linked to a portion of one antibody molecule. 제1항 내지 6항 중 어느 한 항의 포합체를 투여하는 것으로 이루어지는 포유류, 특히 사람의 활성 면역치료법.An active immunotherapy for mammals, in particular humans, comprising administering the conjugate of any one of claims 1 to 6. 제1항 내지 6항 중 어느 한 항의 포합체를 투여하는 것으로 이루어지는 포유류, 특히 사람의 항종양 반응 유발법.A method of inducing anti-tumor response in a mammal, in particular a human, comprising administering the conjugate of any one of claims 1 to 6. 제14항에 있어서, 항종양 반응이 종양 관련 항원(TAA)에 대하여 유도되는 방법.The method of claim 14, wherein the antitumor response is directed against a tumor associated antigen (TAA). 제15항에 있어서, 항종양 반응이 고분자량의 흑종과 관련된 항원에 대하여 유도되는 방법.The method of claim 15, wherein the anti-tumor response is directed against antigens associated with high molecular weight melanoma. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019950005739A 1994-03-21 1995-03-20 Antibody conjugates with improved properties KR950031111A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94810173 1994-03-21
EP94810173.8 1994-03-21

Publications (1)

Publication Number Publication Date
KR950031111A true KR950031111A (en) 1995-12-18

Family

ID=8218230

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950005739A KR950031111A (en) 1994-03-21 1995-03-20 Antibody conjugates with improved properties

Country Status (11)

Country Link
JP (1) JPH0820545A (en)
KR (1) KR950031111A (en)
AU (1) AU1481795A (en)
CA (1) CA2144936A1 (en)
FI (1) FI951276A (en)
HU (1) HUT71776A (en)
IL (1) IL113022A (en)
NO (1) NO951061L (en)
NZ (1) NZ270734A (en)
RU (1) RU95104325A (en)
ZA (1) ZA952269B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865737B1 (en) * 2004-02-03 2006-03-31 Anteis Sa BIOCOMPATIBLE RETICLE GEL

Also Published As

Publication number Publication date
FI951276A (en) 1995-09-22
FI951276A0 (en) 1995-03-17
NO951061L (en) 1995-09-22
NZ270734A (en) 1997-05-26
AU1481795A (en) 1995-09-28
NO951061D0 (en) 1995-03-20
IL113022A0 (en) 1995-06-29
IL113022A (en) 2000-02-29
JPH0820545A (en) 1996-01-23
HU9500586D0 (en) 1995-04-28
RU95104325A (en) 1996-12-27
CA2144936A1 (en) 1995-09-22
ZA952269B (en) 1995-09-21
HUT71776A (en) 1996-01-29

Similar Documents

Publication Publication Date Title
FI104539B (en) Process for producing a modified Group B polysaccharide of Neisseria meningitidis or a modified E. coli K1 capsular polysaccharide
CA1340956C (en) Synthetic peptides representing a t-cell epitope as a carrier molecule for conjugate vaccines
EP0245078B1 (en) Enhancement of antigen immunogenicity
AU2003295520B8 (en) Polysaccharide vaccine for Staphylococcal infections
ES2335557T3 (en) CONJUGATES OF PEPTIDO-POLISACARIDO.
JP4171068B2 (en) Vaccine conjugated with modified Meningococcal polysaccharides
RU95105991A (en) Conjugate, vaccine, methods of immunogenicity enhancement, methods of immunization
US6197299B1 (en) Antibody conjugates
EP0610179B1 (en) Target specific antibody-superantigen conjugates and their preparation
US5858363A (en) Target specific antibody-superantigen conjugates and their preparation
CA2360382A1 (en) Use of antibodies for the vaccination against cancer
CA2363991A1 (en) Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobuline to its high affinity receptor
Bitter-Suermann et al. Monoclonal antibodies to polysialic acid reveal epitope sharing between invasive pathogenic bacteria, differentiating cells and tumor cells
CA2333931A1 (en) Polysaccharide vaccine for staphylococcal infections
KR950031111A (en) Antibody conjugates with improved properties
TW213415B (en)
CA1327523C (en) Antigen immunogenicity
Sela Synthetic macromolecular antigens, drugs and vaccines
EP0674907A2 (en) Conjugabes of a antibody and a carrier protein, useful for active immunotherapy
JPH0222300A (en) Immunogen conjugate, its production and generation of immune
AU3798699A (en) Antibody conjugates with improved properties
NZ286599A (en) use of protein antibody conjugate for stimulating an immune response
MXPA98007617A (en) Polysaccharide-peptide-conjugates

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application